Skip to main content
. 2023 Jan 20;15(3):648. doi: 10.3390/cancers15030648

Figure 3.

Figure 3

Anti-HER2 CAR-TILs eradicate autologous tumor cells refractory to TCR-mediated cytotoxicity. Parental MM3 melanoma and MM3 cells with CRISPR-Cas9 disruption of β-2-Microglubulin (B2M KO, Supplementary Figure S5) were cultured with autologous TILs or CAR-TILS. (a,b) Viability was measured by luciferase activity in melanoma cells after 48 h of co-culture with TILs or mRNA generated (a) or virus generated (b) CAR-TILs. (c) IFNγ was measured in the culture supernatant from the same experiment as in (b). (d) Mice bearing B2M CRISPR knockout MM3 melanoma cells were treated with PBS (n = 3), 20 × 106 TILs (n = 3), or 20 × 106 CAR-TILs (n = 3). Arrow indicates treatment start. Data are presented as mean ± standard error of the mean. p values are represented as ** p < 0.01, *** p < 0.001, and **** p < 0.0001.